Madrigal Pharmaceuticals (MDGL) closed at $396.32 on November 3, 2026, down 8.1% from the previous close, on volume of 1,878,198 shares (30-day average 280,374).
Data as of November 3, 2026.
3-Nov-2026
Madrigal posts its first profitable quarter as Rezdiffra reaches $1.1B in year-to-date net sales
Market Chameleon (Tue, 3-Nov 4:51 AM ET)
TipRanks (Tue, 3-Nov 8:40 AM ET)
Madrigal PharmaceuticalsEPS of $1.83, revenue of $431.3M beats by $26.18M
Seeking Alpha News (Tue, 3-Nov 7:06 AM ET)
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Madrigal Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 2-Nov 10:06 AM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Madrigal Pharmaceuticals trades on the NASDAQ stock market under the symbol MDGL.
As of November 3, 2026, MDGL stock price declined to $396.32 with 1,878,198 million shares trading.
MDGL has a beta of -0.18, meaning it tends to be less sensitive to market movements. MDGL has a correlation of 0.00 to the broad based SPY ETF.
MDGL has a market cap of $9.16 billion. This is considered a Mid Cap stock.
Last quarter Madrigal Pharmaceuticals reported $364 million in Revenue and -$1.99 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.33.
In the last 3 years, MDGL traded as high as $615.00 and as low as $133.99.
The top ETF exchange traded funds that MDGL belongs to (by Net Assets): VTI, VB, XBI, VBK, VXF.
MDGL has underperformed the market in the last year with a price return of -5.4% while the SPY ETF gained +11.7%. MDGL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.2% and -11.4%, respectively, while the SPY returned +1.2% and -1.6%, respectively.
MDGL support price is $420.79 and resistance is $441.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDGL shares will trade within this expected range on the day.
